
MICHIGAN STATE UNIVERSITY

PHS Human Subjects and Clinical Trials Information Form R Series



¹ Response to "Are Human Subjects Involved?" must match the response on the R&R Other Project Information form.

- ² A proposal may include both Delayed Onsets and Study Records. Complete the appropriate sections for each portion of the project.
- ³ See NIH definition of clinical trial: <u>https://grants.nih.gov/policy/clinical-trials/definition.htm</u>
- ⁴ Multiple delayed onset studies may be combined in a single delayed onset record.
- These guidelines are generally applicable to NIH R-series proposals. Please refer to the FOA for specific instructions.

Please refer to the NIH Application Guide Section G.500 for details on this form: https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.500-phs-human-subjects-and-clinical-trials-information.htm



Study Record TABLE 1

Exempt Human Subjects Research		
Section 1 Basic Information	Required	
1.1 Study Title	Required	
1.2 Exempt?	YES	
1.3 Exemption Number	Required	
1.4 Clinical Trial Questionnaire	At least one question NO	
1.5 ClinicalTrials.gov Identifier		

Should match selection on PHS Human Subjects and Clinical Trials Information form
 1.4.a "Does the Study Involve Human Participants?" should be answered YES

	Expemption Number (1.3 above)		
	E4 ONLY ¹	All other Exemptions ²	
		YES	
Section 2 Study Population Characteristics	Not Required	Required	
2.1 Conditions or Focus of Study		Required	\rightarrow Up to 20 Entries
2.2 Eligibility Criteria		Required	ightarrow Use dash+space for bulleted list
2.3 Age Limits		Required	
2.4 Inclusion of Women, Minorities & Children		Required	
2.5 Recruitment and Retention Plan		Required	
2.6 Recruitment Status		Required	
2.7 Study Timeline		Required	
2.8 Enrollment of First Subject		Required	
Inclusion Enrollment Report	Not Required	Required	\rightarrow Up to 20 reports per study record
1. Existing Dataset or Resource?		Required	
2. Enrollment Location Type		Required	
3. Enrollment Countries		Optional	ightarrow Autopoulates USA for domestic
4. Enrollment Locations		Optional	\rightarrow Type of location, not name
5. Comments		Optional	
		Required if <u>not</u> using an existing	
Planned Table		dataset or resource	
		Required if using existing dataset	
Cumulative Table		or resource	
Section 3 Protection and Monitoring Plans	Required	Required	
3.1 Protection of Human Subjects	Required	Required	
3.2 Multisite Study?	Required	Required	ightarrow Select "N/A" for Exempt Studies
IRB Plan			
3.3 Data Safety Monitoring Plan	Optional	Optional	
3.4 DSM Board?	Optional	Optional	
3.5 Overall Structure of the Study Team	Optional	Optional	

Section 4 Protocol Synopsis	Do Not Complete	Do Not Complete
Section 5 Other Clincial Trial-related Attachments	Do Not Complete	Do Not Complete
	\checkmark	\checkmark
	Finished.	Finished.
	Attach to PHS Human Subjects	Attach to PHS Human Subjects
	and Clinical Trials Information	and Clinical Trials Information
	form.	form.

¹ Exemption 4 ONLY.

² Any exemption other than E4 only, or any combination of exemptions including E4.

These guidelines are generally applicable to NIH R-series proposals. Please refer to the FOA for specific instructions.

Please refer to the NIH Application Guide Section G.500 for details and content requirements:

https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.500-phs-human-subjects-and-clinical-trials-information.htm



Study Record TABLE 2

Section 1 Basic Information	Required	
1.1 Study Title	Required	
1.2 Exempt?	NO	
1.3 Exemption Number		
1.4 Clinical Trial Questionnaire	At least one question NO	ightarrow 1.4.a "Does the Study Involve Human Participants?" should be answ
1.5 ClinicalTrials.gov Identifier		
Section 2 Study Population Characteristics	Required	
2.1 Conditions or Focus of Study	Required	\rightarrow Up to 20 Entries
2.2 Eligibility Criteria	Required	\rightarrow Use dash+space for bulleted list
2.3 Age Limits	Required	
2.4 Inclusion of Women, Minorities & Children	Required	
2.5 Recruitment and Retention Plan	Required	
2.6 Recruitment Status	Required	
2.7 Study Timeline	Required	
2.8 Enrollment of First Subject	Required	
nclusion Enrollment Report	Required	ightarrow Up to 20 reports per study record
1. Existing Dataset or Resource?	Required]
2. Enrollment Location Type	Required	
3. Enrollment Countries	Optional	\rightarrow Autopoulates USA for domestic
4. Enrollment Locations	Optional	\rightarrow Type of location, not name
5. Comments	Optional	
	Required if not using an existing	
Planned Table	dataset or resource	J
	Required if using existing dataset	
Cumulative Table	or resource	ļ
Section 3 Protection and Monitoring Plans	Required	J
3.1 Protection of Human Subjects	Required]
3.2 Multisite Study?	Required	\rightarrow If YES, contact IRB office to develop sIRB Plan (irb@ora.msu.edu)
IRB Plan	Required if 3.2 = YES	J
3.3 Data Safety Monitoring Plan	Optional	J
3.4 DSM Board?	Optional]
3.5 Overall Structure of the Study Team	Optional	

Section 4 Protocol Synopsis	Do Not Complete
Section 5 Other Clinical Trial-related Attachments	Do Not Complete

¥

Finished. Attach to PHS Human Subjects and Clinical Trials Information form.

These guidelines are generally applicable to NIH R-series proposals. Please refer to the FOA for specific instructions. Please refer to the NIH Application Guide Section G.500 for details and content requirements: <u>https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.500-phs-human-subjects-and-clinical-trials-information.htm</u>



Study Record TABLE 3

Clinical Trial		
Section 1 Basic Information	Required	
1.1 Study Title	Required	
1.2 Exempt?	NO	
1.3 Exemption Number		
1.4 Clinical Trial Questionnaire	All questions YES	
1.5 ClinicalTrials.gov Identifier	Optional	
Section 2 Study Population Characteristics	Required	
2.1 Conditions or Focus of Study	Required	\rightarrow Up to 20 Entries
2.2 Eligibility Criteria	Required	ightarrow Use dash+space for bulleted list
2.3 Age Limits	Required	
2.4 Inclusion of Women, Minorities & Children	Required	
2.5 Recruitment and Retention Plan	Required	
2.6 Recruitment Status	Required	
2.7 Study Timeline	Required	
2.8 Enrollment of First Subject	Required	
Inclusion Enrollment Report	Required	ightarrow Up to 20 reports per study record
1. Existing Dataset or Resource?	Required	
2. Enrollment Location Type	Required	
3. Enrollment Countries	Optional	ightarrow Autopoulates USA for domestic
4. Enrollment Locations	Optional	\rightarrow Type of location, not name
5. Comments	Optional	
	Required if not using an existing	
Planned Table	dataset or resource	
	Required if using existing	
Cumulative Table	dataset or resource	
Section 3 Protection and Monitoring Plans	Required	
3.1 Protection of Human Subjects	Required	
3.2 Multisite Study?	Required	ightarrow If YES, contact IRB office to develop sIRB Plan
IRB Plan	Required if 3.2 = YES	(irb@ora.msu.edu)
3.3 Data Safety Monitoring Plan	Required	
3.4 DSM Board?	Required]
3.5 Overall Structure of the Study Team	Required	

Section 4 Protocol Synopsis	Required]
4.1 Brief Summary	Required	
4.2 Study Design		
4.2.a. Narrative Study Description	Required	
4.2.b. Primary Purpose	Required	
4.2.c Interventions	Required	\rightarrow Up to 20 interventions
4.2.d Study Phase	Required	\rightarrow Select Y/N NIH Phase III
4.2.e. Intervention Model	Required	
4.2.f. Masking	Required	\rightarrow aka Blinding, if YES select type(s)
4.2.g. Allocation	Required	
4.3 Outcome Measures	Required	\rightarrow At least 1 required; up to 50
4.4 Statistical Design and Power	Required	
4.5 Subject Participation Duration	Required	
4.6 Will the study use FDA-regulated intervention?	Required	ightarrow If YES, provide attachment
		\rightarrow File name must be unique to the proposal if more than one study
4.7 Dissemination Plan	Required	record is included
Section 5 Other Clinical Trial-related Attachments	Only include per FOA	

 $\mathbf{1}$

Finished. Attach to PHS Human Subjects and Clinical Trials Information form.

These guidelines are generally applicable to NIH R-series proposals. Please refer to the FOA for specific instructions.

Please refer to the NIH Application Guide Section G.500 for details and content requirements:

https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/general/g.500-phs-human-subjects-and-clinical-trials-information.htm

PHS Human Subjects and Clinical Trials Information

OMB Number: 0925-0001 Expiration Date: 03/31/2020

Please complete the human subjects section of the Research & Related Other Project Information form prior to completing this form.				
The following items are taken from the Research & Related Other Project Information form and displayed here for your reference. Any changes to these fields must be made on the Research & Related Other Project Information form and may impact the data items you are required to complete on this form.				
Are Human Subjects Involved?	Information populated			
Is the Project Exempt from Federal regulations?	from R&R Other Project Information form.			
Exemption number: 1 2 3 4 5 6 1	7 🗌 8			
Answer required and				
If No to Human Subjects system enforced when human subjects is No.	When human subjects is No,			
Does the proposed research involve human specimens and/or data?	applicants answer a single question, provide associated			
If Yes, provide an explanation of why the application does not involve human subjects research.	attachment (as applicable), and			
Required if Yes to human Add Attachment Delete Attachment View Attachment View Attachment	are done with the form unless instructed in announcement to			
Skip the rest of the PHS Human Subjects and Clinical Trials Information Form.	include Other Requested Information attachment.			

If Yes to Human Subjects

Add a record for each proposed Human Subject Study by selecting 'Add New Study' or 'Add New Delayed Onset Study' as appropriate. Delayed onset studies are those for which there is no well-defined plan for human subject involvement at the time of submission, per agency policies on Delayed Onset Studies. For delayed onset studies, you will provide the study name and a justification for omission of human subjects study information.

Other Requested Information

	iment	View Attachment
attachment when specifically requested in the funding		
opportunity announcement text or application guide.		

Click here to extract the Human Subject Study Record Attachment

Study Record(s)

Attach human subject study records using unique filenames.

1) Please attach Human Su	ibject Study 1			Add Attachment Delete Attachment View Attachment
Cannot add a Delayed Onset Study answer No to human subjects ques R&R Other Project Information form		s question on	but will not	set does NOT apply to a study that can be described start immediately (i.e., delayed start). Multiple delayed es can be grouped in a single record.
	Study Title	Anticij Clini Tria	cal	Justification
Required and system enfo onset study. Up to 600 cha be unique within the applic characters of title will show	aracters. Study title must cation. First 150	nust allow clinic cluded in the sa	unding al trials.	Add ttachment Delete Attachment View Attachment Required and system enforced for each delayed onset study. In addition to justification, must include information regarding how the study will comply with the NIH single Institutional Review Board (sIRB) policy prior to initiating any multi-site study, as well as, a plan for the dissemination of NIH-funded clinical trial information.

Cannot add a Study Record if you answer No to h	Human Subjects question on R&R Other Project Information form.
HS = Human Subjects	
CT = Clinical Trials Study Record: PHS	Human Subjects and Clinical Trials Information
	OMB Number: 0925-0001
* Always required field	Expiration Date: 03/31/2020
Section 1 - Basic Information	
1.1. * Study Title (each study title must be unique) Required and system enforced. Up to 600 characters of title will show in application	0 characters. Study title must be unique within the application. First 150 bookmark.
1.2. * Is this Study Exempt from Federal Regulation	ns? Yes No Answer required and system enforced.
1.3. Exemption Number	1 2 3 4 5 6 7 8 If Study Exempt is Yes, must provide exemption number. Exemptions 7 and
1.4. * Clinical Trial Questionnaire — Answers to	o questionnaire required and system enforced. 8 can be used for due dates on/after January 25, 2019.
If the answers to all four questions below are yes, the	his study meets the definition of a Clinical Trial.
1.4.a. Does the study involve human participa	nts? Yes No all Yes AND FOA
1.4.b. Are the participants prospectively assig	then study will be
1.4.c. Is the study designed to evaluate the eff	flagged as a Clinical
1.5. Provide the ClinicalTrials.gov Identifier (e.g., N	
	ional. Provide NCT# for this study, if available.
Section 2 - Study Population Characteristics Clin	icalTrials.gov at time of application. If building on an
	ting study, enter NCT# for ancillary study (if
2.1. Conditions or Focus of Study	
Required and system enforced unless s	tudy is exemption 4. Up to 20 conditions at 255 characters each.
2.2. Eligibility Criteria	
Required and system enforced unless	study is exemption 4 or otherwise noted in opportunity.
Age limits are required and system e	enforced unless study is exemption 4 or otherwise noted in opportunity.
2.3. Age Limits Minimum Age	Dropdown Years Months Months Months
2.4. Inclusion of Women, Minorities, and Children	Required and system enforced unless study is exemption 4. Attachment Viev Weeks
2.5. Recruitment and Retention Plan	Required and system enforced unless study is exemption 4, 1.4.a=No, or otherwise noted in opportunity.
2.6. Recruitment Status	Required and system enforced unless study is exemption

2.7.	Study	Timeline	

If "N/A (No Limit)" Required and system enforced unless study is exemption ecruiting selected, do not Imeline 4, 1.4.a=No, or otherwise noted in opportunity. nrolling by invitation provide Active, not recruiting Required and system enforced numerical min/ 2.8. Enrollment of First Subject Dropdown: Completed unless study is exemption 4, max age. Date: MM/DD/YYYY. Suspended 1.4.a=No, or otherwise noted in Anticipated Terminated (Halted Prematurely) Inclusion Enrollment Report(s) opportunity. Actual Withdrawn (No Participants Enrolled) Inclusion Enrollment Reports required and Add Inclusion Enrollment Report system enforced unless study is exemption

4, 1.4.a=No, or otherwise noted in opportunity.

4 or otherwise noted in opportunity.

Up to 20 Inclusion Enrollment Reports can be added.

Fellowship (F) and Career Development (K) applications to FOAs that do not allow clinical trials cannot propose independent clinical trial studies led by applicant PD/PI. However, proposing studies under the leadership of a sponsor/mentor that allows for clinical trials research experience is encouraged. Answering Yes to all four Clinical Trial Questionnaire questions will not flag the study as a clinical trial. These studies must include HS information, but will receive a system error if information is included in study fields in sections 4 or 5 of form.

ot yet recruiting

Inclusion Enrollment Report

1. * Using an Existing Dataset or Resource	Yes No	Answer required and system enforced.
2. * Enrollment Location Type	Domestic Foreign	Answer required and system enforced. Do not mix domestic and foreign enrollment data on the same inclusion enrollment report.
3 Enrollment Country(ies)		

3. Enfoiment Country(les)

4. Enrollment Location(s)

5. Comments

Up to 500 characters.

Planned

Planned enrollment information is required and system enforced when answer to "Using an Existing Dataset or Resource" question is No. System enforcement relaxed if Comment is provided.

	Ethnic Categories							
Racial Categories	Not Hispan	ic or Latino	Hispanic	Total				
	Female	Male	Female	Male				
American Indian/ Alaska Native	0	0	0	0	0			
Asian	0	0	0	0	0			
Native Hawaiian or Other Pacific Islander	0	0	0	0	0			
Black or African American	0	0	0	0	0			
White	0	0	0	0	0			
More than One Race	0	0	0	0	0			
Total	0	0	0	0	0			

Cumulative (Actual) enrollment information is required and system enforced when answer to "Using an Existing Dataset or Resource" question is Yes. System enforcement relaxed if Comment is provided.

Racial Categories	Ethnic Categories									
	Not Hispanic or Latino			Hispanic or Latino			Unknown/Not Reported Ethnicity			Total
	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	
American Indian/ Alaska Native	0	0	0	0	0	0	0	0	0	0
Asian	0	0	0	0	0	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0
Black or African American	0	0	0	0	0	0	0	0	0	0
White	0	0	0	0	0	0	0	0	0	0
More than One Race	0	0	0	0	0	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0

Report 1 of 1

Section 3 - Protection and Monitoring	Plans
3.1. Protection of Human Subjects	Required and system enforced. Add Attachment Delete Attachment View Attachment
3.2. Is this a multi-site study that will Yes No No If yes, describe the single IRB pl	development applications OR if study is exempt from federal regulations (i.e., Question 1.2a is Yes
3.3. Data and Safety Monitoring Plan	Required and system enforced for CT study. Optional for HS study. nent View Attachment
	Board be appointed for this study? required and system enforced for CT study unless se noted in opportunity. Optional for HS study.
3.5. Overall Structure of the Study Te	Add Attachment Delete Attachment View Attachment
doe Que	are not allowed to complete fields in Section 4 (i.e., will receive system error) if FOA s not allow clinical trials and/or you answered No to one of the Clinical Trial estionnaire questions in Section 1.
4.1. Brief Summary	uired and system enforced for CT studies unless otherwise
noted in opportunity.	
	fields (4.2.a thru 4.2.g) are required and system enforced for s otherwise noted in opportunity.
Up to 32,000 characters.]
	lown list: Treatment; Prevention; Diagnostics; Supportive Care; Screening; n Services Research; Basic Science; Device Feasibility; and Other
4.2.c. Interventions Up to 20 In	Iterventions allowed.
Intervention Type	Dropdown list: Drug (including placebo); Device (including sham); Biological/Vaccine; Procedure/Surgery; Radiation;
Name Description	Up to 200 characters.Behavioral (e.g., Psychotherapy, Lifestyle Counseling); Genetic (including gene transfer, stem cell and recombinant DNA); and Dietary Supplement (e.g., vitamins, minerals)
	Detary Supplement (e.g., vitamine, minerals) Combination Product Diagnostic Test Phase 1 Phase 1/2 Phase 1/2 Phase 2/2
	odown list: Early Phase 1 (or Phase 0); Phase 1; Phase 1/2; se 2; Phase 2/3; Phase 3; Phase 4; and Other
Is this	an NIH-defined Phase III clinical trial? Yes No
	ropdown list: Single Group; Parallel; Cross-Over; If Masking is Yes, you actorial; Sequential; and Other. must select at least 1 of Factorial Factorial Sequential The Participant/Care
4.2.f. Masking Ye	Other

Dropo	down	list:	N/A;	Randomized	; and	Non-rand	omized
-------	------	-------	------	------------	-------	----------	--------

4.2.g. Allocation

N/A Randomized Non-randomized

4.3. Ou		at one Outcome Measure required and system enforced for CT studies unless rise noted in opportunity. Up to 50 Outcome Measures allowed.							
	Name	Up to 255 characters.							
	Туре	Primary Secondary Dropdown list: Primary; Secondary; and Other							
	Time Frame	Up to 255 characters. Other							
	Brief Description	Up to 999 characters.							
4.4. Sta	tistical Design and Powe	r Required and system enforced for CT study unless otherwise noted in opportunity. Delete Attachment View Attachment							
4.5. Su	4.5. Subject Participation Duration Up to 255 characters. Required and system enforced for CT studies unless otherwise noted in opportunity.								
4.6. Wi	ll the study use an FDA-re	egulated intervention? Yes No Answer required and system enforced for CT study unless otherwise noted in opportunity.							
	a. If yes, describe the av vice Exemption (IDE) stat	ailability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational us							
		Required and system enforced if Yes. Add Attachment Delete Attachment View Attachment							
4.7. Dis	ssemination Plan	Required and system enforced for CT study. Generally one Dissemination Plan per application is sufficient. Can attach same plan (unique filenames) in multiple studies.							
Section	n 5 - Other Clinical Trial-re	elated Attachments							
5.1. Oth	er Clinical Trial-related A	ttachments Add Attachments Delete Attachments View Attachments							
		Form supports up to 10 attachments. Attachments only allowed for CT studies. Only include attachments requested in opportunity.							